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Non-renal indications for continuous renal replacement ther- SYSTEMIC INFLAMMATORY RESPONSE
apy. While there is clear support for the use of continuous SYNDROME AND SEPSIS
renal replacement therapy (CRRT) in critically ill acute renal
Sepsis and other inflammatory syndromes representfailure patients, there are other illnesses without renal involve-
the most popular non-renal indications for CRRT. Thement where CRRT might be of value. These include sepsis
and other inflammatory syndromes such as acute respiratory underlying hypothesis is that hemofiltration removes in-
distress syndrome (ARDS) and cardiopulmonary bypass where flammatory mediators (cytokines, complement activa-
removal of inflammatory mediators by hemofiltration is hy- tion products, contact activation products, arachidonicpothesized to improve outcome. Adsorption appears to be the
acid metabolites, and so forth) from the circulation andpredominant mechanism of mediator elimination. However,
thereby dampens the systemic inflammatory responsethe observed hemodynamic improvement can, at least partially,
be attributed to a reduction of body temperature or to fluid while preserving the local effects that are thought to
removal, and the evidence for a clinically important removal be beneficial. This is indeed an attractive hypothesis.
of proinflammatory cytokines remains limited. Continuous and However, at this moment, the evidence for a clinicallytherefore smooth fluid removal may improve organ function
important elimination of inflammatory mediators, as wellin ARDS, after surgery with cardiopulmonary bypass, and in
as the evidence for a beneficial effect of hemofiltrationpatients with refractory congestive heart failure. Continuous
removal of endogenous toxins, eventually combined with inter- on the outcome of septic patients, remains limited [2–5].
mittent hemodialysis, is probably beneficial in inborn errors of
metabolism, severe lactic acidosis, or tumor lysis syndrome. Removal of inflammatory mediators
with hemofiltration
With the exception of endotoxin and the biologically
Continuous renal replacement therapy (CRRT) is of- active form of tumor necrosis factor (TNF), which is a
ten regarded as one of the more important advances in trimer with molecular weight of 54,000 Da, the molecular
intensive care medicine in recent years. The use of CRRT weight of most inflammatory mediators is compatible
in critically ill patients with acute renal failure, combined with convective removal through high-flux membranes
with cardiovascular instability, severe fluid overload, ce- (cut-off 630,000 Da). However, the reported sieving co-
rebral edema or hypercatabolism and high fluid require- efficients are frequently far beneath 1 (Table 1) [5–18].
ments, is widely accepted [1]. CRRT is also used in some One possible explanation is that the membrane cut-off,
non-renal indications, and these are less well established. which has mostly been determined in in vitro conditions,
These non-renal indications are based on the (presumed) is reduced in clinical conditions because of the presence
elimination of inflammatory mediators [such as systemic of a protein layer. Another explanation is binding of the
inflammatory response syndrome (SIRS) and sepsis, circulating mediators either to each other, as in the TNF
acute respiratory distress syndrome (ARDS), and car-
trimer, or to other substances such as aspecific binding
diopulmonary bypass (CPB)], on the removal of fluid
proteins (a2-macroglobulin) or specific binding sub-
(ARDS, CPB, chronic heart failure), or on the elimina-
stances such as the soluble TNF receptor or the
tion of other endogenous toxic solutes (inborn errors
interleukin-1 (IL-1) receptor. Cell-bound mediators and
of metabolism, lactic acidosis, crush injury, tumor lysis
adhesion molecules are also not accessible for removal
syndrome).
through the membrane.
Another pathway of mediator elimination is adsorp-
tion to the membrane. This adsorption is at least semi-Key words: sepsis, inflammatory syndrome, ARDS, cardiopulmonary
bypass. selective and depends on both mediator and membrane
characteristics (abstract; Silvester et al, Blood Purif 1999 by the International Society of Nephrology
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Table 1. Convective removal of mediators the hemofiltered group [30]. Wakabayashi et al showed
lower interleukin (IL)-6 and IL-8 levels during hemofil-Molecular weight
Mediator daltons Sieving coefficient tration compared with a control period in the same pa-
AA metabolites 6600 0.5–0.91 tients [34], and Kellum et al showed lower TNF levels
Bradykinin 61,100 during hemofiltration compared with hemodialysis [27].
Endothelin 62,500 0.19
De Vriese et al found a short-term decrease in the plasmaC3a/C5a 611,000 0.11–0.77
Factor D 624,000 level of proinflammatory cytokines during the first hour
MDS 600–30,000 of hemofiltration and again after changing the filter. This
LPS 667,000
decrease, however, is followed by an increase that ex-LPS fragments ,1000–20,000
TNF-a 617,000 (54,000) 0–0.2 ceeds the baseline level (uncontrolled observation) [28].
sTNFr 630,000–50,000 ,0.1 Most trials on hemofiltration in sepsis have looked at
IL-1 617,500 0.07–0.42
the removal of proinflammatory mediators. The hostIL-1ra 624,000 0.28–0.45
IL-6 622,000 response not only consists of an inflammatory response,
IL-8 68,000 0–0.48 but also of a so-called CARS (compensatory anti-inflam-
IL-10 618,000 0
matory response) with release of anti-inflammatory me-INF-g 620,000
diators such as IL-4, IL-10, IL-11, IL-13, soluble TNFAbbreviations are: AA, amino acid; MDS, myocardial depressant substance;
LPS, lipopolysaccharide; TNF, tumor necrosis factor; sTNFr, soluble tumor ne- receptor, IL-1 receptor antagonist, and growth factors
crosis factor receptor; IL, interleukin; INF-g, interferon gamma. [35]. The preponderance of proinflammatory or anti-
inflammatory mediators determines whether the result
is hyperinflammation or immunosuppression. High lev-
els of both proinflammatory and anti-inflammatory me-15:127, 1997) [8, 9, 12, 14, 18–26]. In general, the poly-
diators have been associated with mortality, and we stillacrylonitrile membrane seems to have the highest ad-
do not know which patient at which time point needssorptive capacity. This adsorption, however, reaches sat-
more proinflammatory or more anti-inflammatory sub-uration within a few hours. A quantitative important
stances, nor are there routine parameters that allow uselimination therefore not only requires filters with a large
to determine whether the patient is on one or the other
surface area but also frequent changing of the mem-
side of the balance. If hemofiltration removes both proin-
brane. Kellum et al recently compared hemodialysis and flammatory and anti-inflammatory mediators to the same
hemofiltration in a cross-over design in septic patients extent, the net result may be zero. If, on the other hand,
and observed that only hemofiltration is associated with hemofiltration selectively removes proinflammatory or
a decrease of the TNF plasma level. There were, how- anti-inflammatory mediators, the resulting imbalance
ever, no important amounts of TNF in the filtrate, sug- may as well be harmful as beneficial. Lonnemann et
gesting adsorptive elimination and leading to the hypoth- al demonstrated an increase of the ratio of the anti-
esis that convective transport increases adsorption inflammatory soluble TNF receptor to the proinflamma-
caused by exposure of the filtrate to the whole inner tory TNF-a during hemofiltration with a polyamide
structure of the membrane (AN69) representing a tre- membrane [19]. De Vriese et al, on the other hand, found
mendous increase of the available surface [27]. De Vriese a stable balance between TNF and its soluble receptors
et al calculated cytokine mass balances during hemofil- and between IL-1 and its receptor antagonist during he-
tration in septic patients with acute renal failure and mofiltration with an AN69 membrane [28].
demonstrated that adsorption is the predominant clear-
ance mechanism (AN69 membrane), is the most pro- Clinical effect of hemofiltration in systemic
inflammatory response syndrome and sepsisnounced during the first hour and decreases steadily
thereafter. At a higher blood flow rate and filtration rate, A statistically significant effect of zero-balanced he-
the adsorptive as well as the convective elimination was mofiltration on the short-term survival or the survival
increased, either because the amount delivered per unit time of septic animals is found in three of six studies
of time increases or because the higher transmembrane [36–41]. Grootendorst et al and Lee et al, both demon-
pressure pushes the molecules deeper into the mem- strating a beneficial effect, used very high filtration rates
brane and thus increases the adsorptive surface area [28]. of more than 100 ml/kg/hr [38, 40]. In these animal stud-
However, despite their filtration and/or adsorption, ies, the hemofiltration procedure was started before or
most controlled clinical trials do not show an effect of shortly after the septic insult, which is mostly not achiev-
hemofiltration on cytokine plasma levels [29–33]. This able in clinical practice. Moreover, experimental sepsis
is not unexpected in view of their high endogenous clear- was induced by infusion of endotoxins or bacteria, re-
ance compared to which the extracorporeal clearance is sulting in a hypodynamic shock that did not correspond
probably irrelevant [2]. Braun et al, on the other hand, with the hyperdynamic picture seen in clinical sepsis. In
this regard, it is interesting to note that Freeman, usingfound a somewhat more pronounced decrease of TNF in
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a true infection model of chronic intraperitoneal sepsis, versus dialysis [50]. Matamis et al showed that mean
arterial pressure is higher in patients developing hypo-did not establish an effect on survival and even a trend
toward improved survival in the control group [41]. In thermia during hemofiltration [51]. He also found an
inverse relationship between the decrease of body tem-a subsequent study, Lee et al showed that the use of
membranes with a very large pores, resulting in a cut- perature and the filtration rate, which could explain the
hemodynamic effect of high-volume hemofiltration.off of approximately 100,000 Da, leads to a further in-
crease in survival [42]. The effect of zero-balanced hemofiltration on oxygen-
ation in experimental sepsis [38, 39, 45, 46, 52, 53] wasRandomized controlled clinical trials comparing he-
mofiltration with no extracorporeal treatment in patients evaluated in six studies of which only one, using high
volume hemofiltration, established a positive effect [45].with inflammatory syndromes do not establish an effect
on survival. However, the patient numbers in these stud- Cosentino et al found a better oxygenation in a control
group of ARDS patients compared with a group treatedies are small, and the trends are in favor of the hemofilt-
ered group [30–32, 43, 44]. Taking into account the lack with zero-balanced hemofiltration [43]. Manasia et al
(abstract; Manasia et al, Blood Purif 13:393, 1995), Wa-of power of these studies, we have to conclude that
a beneficial effect of hemofiltration on survival is not kabayashi et al [34], and Riera et al [44], on the other
hand, found an improved oxygenation in the filteredestablished, but neither is it excluded.
In animal studies, only two investigators, using very group, but none of these studies gave information on
the fluid balance in the control group.high filtration rates of more than 150 ml/kg/hr, estab-
lished an effect of zero-balanced hemofiltration on the Some authors looked beyond the cardiopulmonary ef-
fect and evaluated the influence of hemofiltration onarterial blood pressure of septic animals or animals with
gut ischemia [abstract; Rogiers et al, Intensive Care Med the immune system. Lonnemann showed that endotoxin-
induced TNF production by monocytes is decreased in22(Suppl 3):S396, 1996] [40, 45]. A positive effect on
cardiac output or other parameters of myocardial con- septic patients and increases during hemofiltration, sug-
gesting the elimination of an anti-inflammatory sub-tractility, pointing to the elimination of a myocardial
depressant substance, is a more consistent finding [ab- stance (abstract; Lonnemann, Blood Purif 15:6, 1997).
Hoffmann et al, on the other hand, reported that in vitrostracts; Rogiers et al, Intensive Care Med 22(Suppl 3):
S396, 1996, and Flynn et al, Anesth Analg 80:S129, 1995] exposure to the ultrafiltrate of septic patients stimulates
LPS-induced TNF production by monocytes, suppresses[36, 37, 40, 45, 46]. However, other investigators, includ-
ing those who use true infection models, did not find an lipopolysaccharide-induced IL-6 production by mono-
cytes, and suppresses IL-2 and IL-6 release from lympho-effect of hemofiltration on the hemodynamic parameters
of septic animals [38, 39, 41, 47, 48]. cytes [15]. DiScipio and Burchard demonstrated that
CAVH attenuates the up-regulation of phagocytosis inA few controlled clinical trials compared zero-bal-
anced hemofiltration with no extracorporeal treatment septic animals [48]. The significance of these findings
remains to be proven.in patients with SIRS or sepsis. Cosentino et al did not
find a statistically significant difference in the hemody-
Conclusionnamic parameters of ARDS patients [43]. Five random-
ized controlled studies in patients with sepsis or severe Although the evidence for a clinically important elimi-
nation of proinflammatory mediators is not very strong,polytrauma found an attenuation of the hyperdynamic
response [abstract; Armbruster et al, Intensive Care Med hemofiltration appears to have some effect in patients
with sepsis and other inflammatory syndromes. The20(Suppl 2):S2, 1994] [29, 31, 32, 44]. These studies there-
fore do not confirm the elimination of a myocardial de- mechanisms of this effect, however, remain unclear.
Studies looking at mediator elimination suggest that ad-pressant factor suggested by the animal studies. Waka-
bayashi et al observed a higher mean arterial pressure sorption is the most important clearance mechanism.
Studies looking at the hemodynamic effect suggest thatduring hemofiltration than during the control period be-
tween two treatments [34]. Using a cross-over design in high filtration rates are important. These findings are
now reconciled by two recent studies suggesting thatseptic patients, Bellomo et al compared high-volume
hemofiltration (filtration rate 6 liters/hr) with low-vol- high filtration rates increase adsorption. As long as we do
not know the exact mechanism underlying the beneficialume hemofiltration (filtration rate 1 liters/hr). Prelimi-
nary results on six patients showed a decrease in vaso- effect of hemofiltration, we are not able to define the
optimal operational characteristics of the hemofiltrationpressor requirement during high-volume treatment [49].
Whether the observed hemodynamic effects can be procedure. Should we use membranes with a high ad-
sorptive capacity? Probably yes, but how frequentlyattributed to the removal of mediators remains to be
proven. A recent study by Van Kuijk showed that the should they be changed? Should we use large-pore mem-
branes, as suggested by the latest animal studies, orextracorporeal blood temperature plays a critical role in
the improved hemodynamic tolerance of hemofiltration should we use very high filtration rates, and how high
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should these be? These are all questions that need to be alone or if the removal of inflammatory mediators also
answered before large randomized trials can be designed. contributes to these effects.
The results of these trials should be awaited before the To answer this question, Journois et al performed a
widespread use of hemofiltration in septic patients with- randomized trial in which they compared simple ultrafil-
out renal failure can be recommended. tration with high-volume, zero-balanced hemofiltration
followed by ultrafiltration in children undergoing surgi-
cal correction of congenital heart disease under hypo-ACUTE RESPIRATORY DISTRESS SYNDROME
thermic CPB [61]. Immediately after hemofiltration, the
Beside the eventual elimination of inflammatory medi- hemofiltered group had lower levels of C3a and TNF.
ators, fluid removal with reduction of extravascular lung However, after 24 hours, the difference in TNF was more
water (EVLW) is a second mechanism by which hemo- pronounced and also the levels of IL-1, IL-6, and IL-8
filtration may be beneficial in ARDS. Fluid management were lower at this time point. The author therefore con-
in ARDS remains controversial. Theoretically, a reduc- cludes that hemofiltration removes cytokine-inducing
tion of the hydrostatic pressure in the pulmonary circula- substances. The dampened inflammatory response is
tion will reduce the pressure gradient driving the for- manifested clinically as a lower body temperature, less
mation of edema. Indeed, Humphrey et al showed that blood loss, lower neutrophyl count, and less oxidative
a reduction in pulmonary capillary wedge pressure damage to the lungs [61].
(PCWP) is associated with an improved survival in
ARDS patients. However, what they actually showed
was a better survival in the patients who responded to CONGESTIVE HEART FAILURE
diuretics, dialysis, or ultrafiltration with a lowering of In congestive heart failure (CHF), the reduced sys-
PCWP compared with patients in whom the same treat- temic blood flow is perceived as a reduced effective circu-
ment had no effect on the wedge pressure. In other lating volume resulting in the activation of several neuro-
words, they were probably comparing different patients humoral systems such as the sympathetic system and the
[54]. Laggner et al compared the effect of ultrafiltration renin-angiotensin-aldosterone system, and in the release
on the EVLW of patients with cardiogenic pulmonary of vasopressin. This inappropriate activation results in
edema and ARDS, and showed a decrease of the shunt arteriolar vasoconstriction (further increasing the after-
fraction in both groups. However, the reduction of load) and in water retention caused by enhanced renal
EVLW was less pronounced in ARDS patients in whom sodium reabsorption leading to an increase in filling pres-
hemofiltration also induced a decrease of cardiac output sures and edema. The treatment of refractory CHF re-
and O2 delivery [55]. Ultrafiltration in ARDS patients quires an interruption in the vicious neurohumoral he-
should therefore be performed only under close hemody- modynamic cycle, and this can mostly be achieved with
namic monitoring. diuretics, vasodilators, and b-blocking agents [62].
Continuous renal replacement therapy-induced hypo- Some patients remain refractory to this medical treat-
thermia can be used in patients with ARDS in order
ment, and in these patients, the removal of fluids and
to reduce CO2 production. The decreased ventilatory sodium can be achieved with simple ultrafiltration. Ca-
requirement reduces the risk of ventilator-induced lung
naud treated 52 patients with chronic heart failure andinjury. Reduced CO2 production combined with the alka- New York Heart Association (NYHA) class IV withlinizing effect of bicarbonate in the replacement solution
isolated ultrafiltration. In 35 surviving patients, ultrafil-facilitates the institution of permissive hypercapnia [56].
tration resulted in an increase of diuresis and sodium
excretion, and a further decrease of body weight after
CARDIOPULMONARY BYPASS interruption of the procedure. Despite fluid removal,
arterial pressure remained stable and patients recoveredAnother possible indication for hemofiltration is sur-
to NYHA class II or III [63].gery with cardiopulmonary bypass (CPB). CPB, espe-
Other authors also report a decrease of neuroendo-cially in children, results in tissue edema, pulmonary
crine factors such as norepinephrine, aldosterone, vaso-dysfunction, and poor cardiac performance caused by
pressin, and plasma renin activity, a striking increase ofhemodilution and fluid overload and to activation of the
water and sodium excretion, a more sustained improve-inflammatory response. Isolated ultrafiltration, during
ment in functional capacity than with supplementaryand especially after CPB, in children has been shown to
doses of loop diuretics, a re-established response to tradi-reduce weight gain, blood loss, and transfusion require-
tional medical treatment, and an improvement of thement, to improve left ventricular systolic and diastolic
quality of life [64–70]. Recently established guidelinesfunction, to decrease pulmonary vascular resistance and
for the treatment of chronic heart failure (Task Forceto improve oxygenation [57–60]. It remains unclear, how-
ever, if these beneficial effects are due to fluid removal of the Working Group on Heart Failure of the European
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Society of Cardiology) mention ultrafiltration as an aid TUMOR LYSIS SYNDROME
to gain time while waiting for a transplantation [62]. Tumor lysis syndrome may lead to renal failure caused
by tubular obstruction by uric acid crystals or to hyper-
phosphatemia with precipitation of calcium/phosphateINBORN ERRORS OF METABOLISM
complexes in renal interstitium and tubuli [88]. Both uric
Children with maple syrup urine disease, urea cycle acid and phosphate are small molecules that require a
disorders, and organic acidemia can produce high levels highly diffusive clearance, and conventional dialysis is
of branched-chain amino acids and hyperammonemia, certainly more effective than the continuous techniques;
inducing irreversible damage, especially in the central however, CRRT can been used in unstable patients or
nervous system. Continuous venovenous hemofiltration in combination with intermittent dialysis [89, 90]. The
(CVVH) and especially continuous venovenous hemodi- prevention of ARF in tumor lysis syndrome relies on
alysis (CVVHD) are rapidly effective in clearing these the stimulation of diuresis combined with allopurinol.
low molecular weight toxic metabolites, allowing the pa- CRRT has been used to prevent ARF in high-risk pa-
tients to recover their neurological status [71–75]. tients, who were defined based on the level of LDH and
the urine output [91].
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tration, by extracorporeal elimination of lactate, may
contribute to the correction of lactic acidosis [76–78]. REFERENCES
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